Immunoglobulin therapy for immunodeficiency.

Immunoglobillin replacement is donor-derived pooled iminuiloglobillin G, tuhich provides passive immimity to patients zoith antibody deficiency or dysfunction. It may be administered via either intravenous or subcutaneous routes. Intravenous immunoglobitlin is administered at higher doses every 3-4 weeks, whereas most forms of subclitaneolts imllittlloglobulin are administered at lower doses, usually every 1-2 weeks. Benefits and risks, including adverse effects, conuenience, and cost vary according to route of administration. Immunoglobulin products also differ in their composition, so patient-specific comorbidities are important to consider when selecting an imilittiloglobillin product. We discuss adverse effects associated with immunoglobitlin therapy, their associated risk factors, treatment, and ways to mitigate these risks. Finally, the laboratory monitoring and vaccination recommendations for patients on immunoglobulin replacement therapy are reviewed. [ABSTRACT FROM AUTHOR]